Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin

Early Phase 1

Completed

Conditions: Drug Interactions
Pharmacokinetics

Interventions: Drug: Daptomycin
Drug: Rifampin

First Posted Date: 2014-03-27

Last Posted Date: 2016-12-12

Lead Sponsor: University of Utah

Target Recruit Count: 12

Registration Number: NCT02097953

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: E2609
Drug: itraconazole
Drug: rifampin
Drug: digoxin
Drug: donepezil

First Posted Date: 2014-02-05

Last Posted Date: 2015-11-03

Lead Sponsor: Eisai Inc.

Target Recruit Count: 195

Registration Number: NCT02055703

Locations: 🇺🇸
WCT Early Development, San Antonio, Texas, United States

To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: selumetinib
Drug: rifampicin

First Posted Date: 2014-01-28

Last Posted Date: 2014-04-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT02046850

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

Phase 2

Completed

Conditions: Sarcoidosis; Antimycobacterial Therapy

Interventions: Drug: Placebo
Drug: Levofloxacin
Drug: Ethambutol
Drug: Azithromycin
Drug: Rifampin

First Posted Date: 2013-12-31

Last Posted Date: 2020-07-09

Lead Sponsor: Vanderbilt University

Target Recruit Count: 97

Registration Number: NCT02024555

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Vanderbilt University School of Medicine, Nashville, Tennessee, United States

and more 3 locations